ROCKET PHARMACEUTICALS INC (RCKT)
US77313F1066 - Common Stock
First Week of June 21st Options Trading For Rocket Pharmaceuticals (RCKT)
RCKT Crosses Below Key Moving Average Level
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
FDA extends review period for Rocket gene therapy to June 30 (NASDAQ:RCKT)
Rocket Pharmaceuticals (RCKT) said the FDA has extended the priority review period for its gene therapy product Kresladi for the treatment of severe Leukocyte A
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.
First Week of March 15th Options Trading For Rocket Pharmaceuticals (RCKT)
First Week of RCKT February 16th Options Trading
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
Interesting RCKT Put And Call Options For July 2024
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals Stock Sees Improved Price Strength
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78
Rocket Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for RCKT
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully
Its near-term risks are subtle but bigger than their flying stock price might indicate.
First Week of RCKT November 17th Options Trading
Notable Wednesday Option Activity: RCKT, MDGL, CYTK
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?
With Rocket Pharmaceuticals reaching a Phase II agreement with the FDA, RCKT stock soared, though some concerns linger.
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.